⌕
MBX Biosciences · MBX · Nasdaq
Tenet 53 · Mixed
Compare
$53.10−0.04%At closeTenet 53 · Mixed
$53.10−0.02 (−0.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

MBX Biosciences (MBX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼40.5%
−87.0
FY23→FY25CAGR —
Free cash flow ($M)▼47.4%
−81.9
FY23→FY25CAGR —
Diluted EPS▲59.1%
−2.38
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−79.2R&D−18.9SG&A−98.1Op income11.1Tax & other−87.0Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY23FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7518, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
—0.00.00.0——
Cost of revenue
—0.00.00.0——
Gross profit
—0.00.00.0——
Research & development
101.379.257.428.5▲37.9%+66.6%
Selling, general & admin
59.118.910.86.8▲75.3%+67.0%
Total operating expenses
160.398.168.235.3▲43.8%+66.6%
Operating incomefeeds ROC rank
−160.3−98.1−68.2−35.3▼43.8%—
Other income, net
15.211.16.32.7——
Pretax income
−145.1−87.0−61.9−32.6▼40.5%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−145.1−87.0−61.9−32.6▼40.5%—
Per share
Diluted EPSbuyback-sensitive
−3.03−2.38−5.82−31.96▲59.1%—
Diluted shares (mn)
48.5636.5110.641.02▲243.0%+498.6%
Margins
† TTM = trailing four quarters through 2026-09-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.